))
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations
Manage episode 407461996 series 3560609
Content provided by Jacqueline Stone and Oncololgy News Central. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and Oncololgy News Central or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Updates to the American Society for Clinical Oncology’s (ASCO’s) living guidelines for therapy in patients with stage IV non-small cell lung cancer (NSCLC) with driver alterations were recently released. Dwight H. Owen, MD, MS, from The Ohio State University Comprehensive Cancer Center – James, examines the new recommendations that he and his team introduced with Bob Figlin, MD, the Steven Spielberg family chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles. They discuss how the living guidelines are updated and the rationale for what gets included, a process Dr. Figlin notes is “critical to the practicing oncologist.” Dr. Owen describes three new additions that are “really impactful” and his hopes for how these will directly improve patient care.
120 episodes
Share
